The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Meanwhile, 6.1% of those taking Zepbound stopped the trial because of adverse reactions, compared to 8 ... considering the current market leaders like Zepbound and Wegovy are administered via ...

that aims to compete with Eli Lilly's Zepbound. Shares of this small-cap biotech are likely to remain volatile, but have significant long-term upside potential. Every market leader started ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... but some have experienced more serious reactions, such as pancreatitis," she told Fox News ...